急性心力衰竭藥物治療新進(jìn)展-文庫吧
2025-09-07 17:56 本頁面
【正文】 ebinant form of human Btype natriuretic peptide, is a venous and arterial vasodilator with a bined modest diuretic and natriuretic effect. Intravenous nesiritide may be initiated with or without a bolus infusion. Noninvasive BP measurements are usually adequate. Combination with other . vasodilators is not remended. Nesiritide is not available in most European countries. ESC GUIDELINES。 European Journal of Heart Failure (2020), 933– 989 NESIRITIDE (. DRUGS AND INTERVENTIONS UNDER ACTIVE INVESTIGATION) Promote diuresis and natriuresis, have vasodilatory properties, lead to an indirect increase in cardiac output, and suppress neurohormonal activation。 they have been approved for use in the management of acute HF. In this setting, nesiritide has been shown to improve symptoms of acute HF, but the effect on morbidity and mortality has not been clear from available clinical are currently under investigation as adjunctive therapy。 Unless a definitive study does demonstrate safety and efficacy, intermittent or continuous outpatient infusion of nesiritide and other natriuretic peptides is not remended. 2020ACCF/ AHA heart failure guideline。 JACC,2020， 53（ 15）， E190. ASCENDHF研究 N Engl J Med 2020。365:3243. ASCENDHF研究 N Engl J Med 2020。365:3243. ASCENDHF研究 N Engl J Med 2020。365:3243. ASCENDHF研究 N Engl J Med 2020。365:3243. ASCENDHF研究結(jié)論 N Engl J Med 2020。365:3243. 主要內(nèi)容 急性心力衰竭現(xiàn)狀 急性心力衰竭治療藥物新進(jìn)展 1. rhBNP 正性肌力藥物 正性肌力藥物適用于低心排綜合癥，如伴癥狀性低血壓或 CO降低伴有循環(huán)淤血的患者，可緩解組織低灌注所致的癥狀，保證重要臟器的血流供應(yīng)，血壓較低和對血管擴(kuò)張藥物利尿劑不耐受或反應(yīng)不佳的
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1